Agendia B.V. (Agendia) has appointed Alan B. Carter as the company’s new vice president (VP) of global business development. Carter brings 25 years of business development, sales and marketing experience from a number of top tier life sciences companies such as BioTrove, Celera, Applied Biosystems and Perkin Elmer. At Agendia, Carter will assume responsibility for strategic business opportunities to build on the current success of Agendia’s molecular diagnostics portfolio.
This products suite includes MammaPrint, the only FDA approved test for rapidly and accurately diagnosing therapeutic options for breast cancer patients. Additionally, he will play an important role in forging Agendia’s strategic alliances with pharmaceutical and biotech companies to accelerate the use of molecular diagnostics in drug development, companion diagnostics and safety testing programs.
“As we continue to grow as a global company, Alan’s appointment furthers one of our primary aims,” commented Bernhard Sixt, president and chief executive officer. “His extensive business development expertise will strengthen our ongoing programs and pipeline projects and also allows us to capitalize on our genomics platform in close collaboration with biotechnology and pharmaceutical partners. With Alan’s involvement, Agendia will continue to play a central role in making targeted therapies one of the cornerstones of personalized medicine.”